You are here

Article Text

Article menu
Download PDFPDF
DTB commentary
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF)
  1. Elizabeth Adeyeye1,
  2. Teck K Khong2
  1. 1 St George's University of London, London, UK
  2. 2 Clinical Pharmacology, St George's University of London, London, UK
  1. Correspondence to Dr Teck K Khong, Clinical Pharmacology, St George's University of London, London SW17 0RE, UK; tkhong{at}sgul.ac.uk

Abstract

Commentary on: Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 2021; 385:1451–61.

  • Heart failure
  • Cardiovascular Diseases

http://dx.doi.org/10.1136/dtb.2022.000060

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Series co-ordinator Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George’s, University of London, UK

    • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.